Sorafenib, a small molecule multikinase inhibitor, is the standard of care in the USA and Europe for the treatment of advanced hepatocellular carcinoma. This article reviews its development from the basis of molecular hepatocarcinogenesis to phase III trials and discusses the future for sorafenib in hepatocellular carcinoma.
PDF的下载单位、IP信息已删除
(2025-6-4)
张欢馨
Nole
yjh123
东方元语
cdercder
xing_xing
行走的荷尔蒙
1104481279
woshi123
科研狗
OK
ddd
Kao
ming2026
殷勤的紫槐
huang
aajhajkahna
天晴
Criminology34
渡人舟
皖公网安备34019202002308
